Fortunately, asciminib was approved by the US FDA to treat CML patients who treated with two prior TKIs or with BCR-ABL-T315I mutation in 2021. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.